-

Feinstein Institutes awarded $3.6M from New York State for spinal cord injury research

MANHASSET, N.Y.--(BUSINESS WIRE)--The spinal cord plays a vital role in the human body – it acts as the information highway sending signals to and from our brain, helping to control our movements and process sensations. When someone suffers a spinal cord injury (SCI) it can lead to paralysis, sometimes in all four limbs. To better understand what happens to the brain and body after a SCI and to develop new methods of treatment using bioelectronic medicine to regain movement and sensation, researchers at The Feinstein Institutes for Medical Research have been awarded a five-year, $3.6 million grant from the New York State Department of Health to study spinal cord stimulation and novel brain implant technology.

The research study, led by Chad Bouton, vice president of advanced engineering and professor at the Institute of Bioelectronic Medicine at the Feinstein Institutes, along with co-principal investigators Ashesh Mehta, MD, PhD, from the Feinstein Institutes, and Susan Harkema, PhD, at the University of Louisville, will assess if cervical stimulation – alone and in combination with brain implants – could promote lasting movement.

“Losing movement in all four limbs makes tasks like getting out of bed, brushing your teeth, and getting dressed impossible. There is a drastic deterioration in quality of life and currently there is no cure for permanent paralysis,” said Prof. Bouton, the study’s principal investigator. “With the state’s generous support, we have the potential to study new bioelectronic medicine solutions that could restore movement for those living with spinal cord injuries.”

Previous research from Prof. Bouton, Dr. Santosh Chandrasekaran, a researcher with the Feinstein Institutes, and their colleagues shows that cervical stimulation applied at the base of the neck can lead to improved recovery after injury. The new study will analyze the combination of cervical stimulation and brain-computer interface (BCI) technology that involves the placement of multiple small “chips” (tiny micro-electrodes) in the brain. Researchers will enroll 12 participants who will receive over-the-skin spinal cord stimulation for 12 months, and two participants will begin with over-the-skin stimulation for several months, followed by six months of BCI-driven over-the-skin spinal cord stimulation to facilitate further recovery.

Through activity-based and BCI-assisted training sessions, individuals with SCI will conduct tasks while receiving cervical stimulation. The goal is to observe the stimulation’s effect on the brain’s activity patterns and arm and hand movements to restore long-term control of the muscles.

“New York State support of this project comes at a critical time as advances in bioelectronic medicine continue to make progress towards enhancing mobility in patients with spinal cord injury,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. “This also supports an important and productive collaboration between Feinstein Institutes’ Chad Bouton and his team with the University of Louisville team led by Susan Harkema, PhD.”

The Feinstein Institutes is the scientific home of bioelectronic medicine, the scientific field that combines molecular medicine, neuroscience and biomedical engineering to develop innovative therapies using computer chips and devices instead of drugs to treat various diseases and conditions through the stimulation of nerves, including paralysis.

About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Julianne Mosher Allen
516-880-4824
jmosherallen@northwell.edu

The Feinstein Institutes for Medical Research


Release Versions

Contacts

Julianne Mosher Allen
516-880-4824
jmosherallen@northwell.edu

More News From The Feinstein Institutes for Medical Research

32BJ Health Fund and Northwell Direct Announce Largest Direct Healthcare Contract of its Kind in the Country, Delivering Major Savings and Expanding Access to Care

NEW YORK--(BUSINESS WIRE)--32BJ Health Fund, the union health fund representing 100,000 building service workers in the New York metro area, and Northwell Direct, a direct-to-employer health care network that partners directly with employers and labor unions to provide health benefits solutions to their employees, today announced a historic deal that will significantly expand access to high-quality care for 32BJ members and their families while delivering dramatic savings to patients, unions an...

Feinstein Institutes’ Researchers Develop Promising Therapeutic for Sepsis-Induced Acute Lung Injury

MANHASSET, N.Y.--(BUSINESS WIRE)--Scientists at Northwell Health’s Feinstein Institutes for Medical Research are making strides in controlling the severe inflammation that is the hallmark of sepsis. This severe condition occurs when the body’s immune system reaction to infection causes it to attack its own tissues and organs, often resulting in organ failure or death. Researchers have uncovered a critical mechanism driving acute lung injury (ALI) in sepsis, identifying a novel subset of neutrop...

Northwell Health’s Feinstein Institutes’ Dr. Kevin J. Tracey Elected to National Academy of Inventors’ 2025 Class of Fellows

MANHASSET, N.Y.--(BUSINESS WIRE)--Recognized for his discovery of the inflammatory reflex and the burgeoning field of bioelectronic medicine, Kevin J. Tracey, MD, president and CEO of The Feinstein Institutes for Medical Research, has been named a Fellow of the National Academy of Inventors (NAI) as part of its 2025 Class. This prestigious recognition is the highest professional distinction awarded solely to inventors. The honor acknowledges those who have demonstrated a spirit of innovation in...
Back to Newsroom